---
title: "Enliven Therapeutics Announces Oral Presentation at the EHA 2026 Congress Featuring Additional Positive Phase 1 Clinical Trial Data for ELVN-001 in CML | ELVN Stock News"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286114157.md"
description: "Enliven Therapeutics Announces Oral Presentation at the EHA 2026 Congress Featuring Additional Positive Phase 1 Clinical Trial Data for ELVN-001 in CML | ELVN Stock News"
datetime: "2026-05-12T05:55:28.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286114157.md)
  - [en](https://longbridge.com/en/news/286114157.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286114157.md)
---

# Enliven Therapeutics Announces Oral Presentation at the EHA 2026 Congress Featuring Additional Positive Phase 1 Clinical Trial Data for ELVN-001 in CML | ELVN Stock News

Enliven Therapeutics Announces Oral Presentation at the EHA 2026 Congress Featuring Additional Positive Phase 1 Clinical Trial Data for ELVN-001 in CML | ELVN Stock News

### Related Stocks

- [ELVN.US](https://longbridge.com/en/quote/ELVN.US.md)

## Related News & Research

- [16:05 ETEnliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update](https://longbridge.com/en/news/285607145.md)
- [Enliven Therapeutics (ELVN) Projected to Post Earnings on Wednesday](https://longbridge.com/en/news/285371284.md)
- [Evaxion to present new data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia, at the EHA 2026 Congress | EVAX Stock News](https://longbridge.com/en/news/286109610.md)
- [SELLAS Life Sciences Nears Pivotal Trial Readout As Leukemia Pipeline Progresses](https://longbridge.com/en/news/286279161.md)
- [A Look At Nurix Therapeutics (NRIX) Valuation After New NX-5948 Data And EHA Congress Selection](https://longbridge.com/en/news/286784826.md)